drugset / Trial / NCT06814119

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

NCT06814119

Phase 1 Completed 34 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of calderasib when it is given to people with RI and if people with RI can tolerate it.

Timeline

Start
2025-04-07
Primary completion
2026-01-23
Completion
2026-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Calderasib Unknown Oral